Jeffrey McCullough - Transfusion Medicine

73 73. Mourad N. Studies on release of certain enzymes from human platelets. Transfusion 1968; 8(6):363–367.

74 74. Murphy S. Platelets from pooled buffy coats: an update. Transfusion 2005; 45(4):634–639.

75 75. Fijnheer R, Pietersz RNI, De Korte D, et al. Platelet activation during preparation of platelet concentrates: a comparison of the platelet‐rich plasma and the buffy coat methods. Transfusion 1990; 30(7):634–638.

76 76. Eriksson L, Hogman C. Platelet concentrates in an additive solution prepared from pooled buffy coats. I. In vitro studies. Vox Sang 1990; 59:140–145.

77 77. Murphy S, Gardner FH. Effect of storage temperature on maintenance of platelet viability—deleterious effect of refrigerated storage. N Engl J Med 1969; 280(20):1094–1098.

78 78. Murphy S, Sayar SN, Gardner FH. Storage of platelet concentrates at 22 degrees C. Blood 1970; 35:549–557.

79 79. Handin RI, Valeri CR. Hemostatic effectiveness of platelets stored at 22°C. N Engl J Med 1971; 285(10):538–543.

80 80. Filip DJ, Aster RH. Relative hemostatic effectiveness of human platelets stored at 4° and 22°C. J Lab Clin Med 1978; 91:618–624.

81 81. Kunicki TJ, Tuccelli M, Becker GA, Aster RH. A study of variables affecting the quality of platelets stored at “room temperature.” Transfusion 2003; 15(5):414–421.

82 82. Scott E, Slichter S. Viability and function of platelet concentrates stored in CPD‐adenine (CPDA‐1). Transfusion 1980; 20(5):489–497.

83 83. Holme S, Vaidja K, Murphy S. Platelet storage at 22°C: effect of type of agitation on morphology, viability, and function in vitro. Blood 1978; 34:403–419.

84 84. Vassallo RR, Wagner SJ, Einarson M, et al. Maintenance of in vitro properties of leukoreduced whole blood‐derived pooled platelets after a 24‐hour interruption of agitation. Transfusion 2009; 49(10):2131–2135.

85 85. Murphy S, Kahn RA, Holme S, et al. Improved storage of platelets for transfusion in a new container. Blood 1982; 60:194–200.

86 86. Simon T, Nelson E, Murphy S. Extension of platelet concentrate storage to 7 days in second‐generation bags. Transfusion 1987; 27(1):6–9.

87 87. Heal J, Singal S, Sardisco E, Mayer T. Bacterial proliferation in platelet concentrates. Transfusion 1986; 26(4):388–390.

88 88. Braine H, Kickler T, Charache P, et al. Bacterial sepsis secondary to platelet transfusion: an adverse effect of extended storage at room temperature. Transfusion 1986; 26(4):391–393.

89 89. U.S. Deparment of Health and Human Services. Biologics guidances. 2019. Available from: https://ww.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/bacterial‐risk‐control‐strategies‐blood‐collection‐establishments‐and‐transfusion‐services‐enh.

90 90. Simon T, Sierra E. Concentration of platelet units into small volumes. Transfusion 1984; 24(2):173–175.

91 91. Moroff G, Friedman A, Robkin‐Kline L, et al. Reduction of the volume of stored platelet concentrates for use in neonatal patients. Transfusion 1984; 24(2):144–146.

92 92. Strauss RG. Current issues in neonatal transfusions. Vox Sang 1986; 51(1):1–9.

93 93. Eastlund T. Monetary blood donation incentives and the risk of transfusion‐ transmitted infection. Transfusion 1998; 38(9):874–882.

94 94. Walsh JH. Posttransfusion hepatitis after open‐heart operations. JAMA 1970; 211(2):261.

95 95. Prince A. Sterilisation of hepatitis and HTLV‐III viruses by exposure to tri(n‐butyl)phosphate and sodium cholate. Lancet 1986; 327(8483):706–710.

96 96. Dichtelmuller H, Biesert L, Fabrizzi R. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics association member companies. Transfusion 2009; 49:1931–1943.

97 97. Foster PR, Welch AG, McLean C, et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000; 78(2):86–95.

98 98. Brown P, Cervenáková L, McShane LM, et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt‐Jakob disease in humans. Transfusion 1999; 39(11–12):1169–1178.

99 99. Kasper C, Lusher J. Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee. Transfusion 1993; 33(5):422–434.

100 100. Aronson D. The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia A. Transfusion 1990; 30(8):748–758.

101 101. Azzi A, Ciappi S, Zakvrzewska K, et al. Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentrates. Am J Hematol 1992; 39(3):228–230.

102 102. An outbreak of hepatitis A related to a solvent/detergent treated factor VIII concentrate (Alphanate). MMWR 1996; 45:29–32.

103 103. Lusher JM, Arkin S, Abilgaard CF, Schwartz RS. Recombinant Factor VIII for the treatment of previously untreated patients with hemophilia A. Surv Anesthesiol 1993; 37(5):307.

104 104. Bray G, Gomperts E, Courter S. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83:2428–2437.

105 105. Kasper CK. Plasma‐derived versus recombinant factor VIII for the treatment of hemophilia A. Vox Sang 1996; 70(S3):17–20.

106 106. Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract 2008; 62(10):1614–1622.

107 107. Mannucci PM, Bauer KA, Gringeri A, et al. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76:2540–2545.

108 108. Fenger‐Eriksen C, Lindberg‐Larsen M, Christensen AQ, et al. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 2008; 101(6):769–773.

109 109. Peyvandi F. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. Thromb Res 2009; 124(Suppl 2):S9–S11.

110 110. Rahe‐Meyer N, Pichlmaier M, Haverich A, et al. Bleeding management with fibrinogen concentrate targeting a high‐normal plasma fibrinogen level: a pilot study. Br J Anaesth 2009; 102(6):785–792.

111 111. Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood 2015; 125(9):1387–1393.

112 112. Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human γ‐globulin. Vox Sang 1962; 7(2):157–174.

113 113. Knezevic‐Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43(10):1460–1480.

114 114. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 2017; 139(3):S1–S46.

115 115. Ratko TA. Recommendations for off‐label use of intravenously administered immunoglobulin preparations. JAMA 1995; 273(23):1865.

116 116. Scaradavou A, Bussel JB. Clinical experience with anti‐D in the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 1998; 35:52–57.

117 117. Rushin J, Rumsey DH, Ewing CA, Sandler SG. Detection of multiple passively acquired alloantibodies following infusions of IV Rh immune globulin. Transfusion 2000; 40(5):551–554.

118 118. McCullough J. Pathogen inactivation: a new paradigm for blood safety. Transfusion. 2007; 47(12):2180–2184.

119 119. Alter HJ. Pathogen Reduction: a precautionary principle paradigm. Transfus Med Rev 2008; 22(2):97–102.